Biotech News & Trading Forum: Community User: Weedmaster

Warum wird das gestern? 😒 $.TYME

$TYME Direct Offering Kandidat mit vielversprechenden Catalysts.

GlycoMimetics GLYC 48m Aktien  $180m MC $127m Cash $3.8m burn/Monat  Catalysts Internal decision on rivipansel H1 ’21 Company expects to initiate Investigational New Drug-enabling work with GMI-1687 during 2021 Apollomics initiates first upro clinical trial H1 ’21 GMI-1359 data read-out from Phase 1b breast cancer trial Q1 ’21 Uproleselan Enrollment complete, R/R pivotal trial 2H ‘21 https://ir.glycomimetics.com/static-files/1bd511b0-01d5-4250-93f6-71fc970e41b1

Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates https://m.benzinga.com/article/19387602

Hoth Therapeutics HOTH 16m Aktien  $35m MC $8m Cash $500k burn/Monat  Drug Pipeline Highlights: BioLexa Platform: Scheduled to begin Phase 1b clinical trial in Q1 2021 Official cohort 1 Results Initiate Phase 1b cohort 2 Patient Dosing in Q2 2021 Phase 1b cohort 2 Results in Q3 2021 Type C FDA Meeting US IND preparation in Q4 2021 HT-001: Granted Pre-IND meeting with FDA with responses targeted for February 22, 2021 GMP Development in Q2 2021 GLP Toxicology Studies in Q3 2021 US IND submission in Q4 2021 HT-002 (COVID-19 Therapy) In vitro studies for peptide effect in Q1 2021 HT-003: Received positive preclinical mechanism of action date for acne treatment and renewal of the preclinical research plan Mouse model studies in Q2 2021 Study results Formulation development in Q3 2021 HT-004: Key proof-of-concept animal model data expected in Q2 2021 Study Results to select oligo actives Submit RFD to FDA in Q2 2021 Initiate non-GLP toxicology in Q3 2021 HT-005 Z-Pods (Cutaneous Lupus Erythematosus) Further preclinical studies in Q1 2021 HT-006 (Antibiotic for VAP/HAP) Research Plan with Univ. Cincinnati/ initiate in vitro studies in Q1 2021 In vitro studies for proof-of- concept in Q2 2021 Mouse Model studies in Q3 2021 https://ir.hoththerapeutics.com/image/HOTH+Winter+2021+Investor+Deck+1-22-2021.pdf

Axh, beim link natürlich stock,twits ohne, reingeben

Artelo heute, als nächstes Citius😉

Ohjr, redd.t wird auch gesternt 🙈

Hi, welche weedstocks haben als Langzeit invest das größte Potential? Ich bin mir sehr sicher, dass weedstocks irgendwann einen noch größeren Hype als 2017 sehen werden und den will ich mitnehmen, mit einer langfristigen Position Ich schwanke grad zwischen Canopy Growth, Tilray, Cresco Labs, Terrascend, Columbia Care und AMP

30 Minuten alt: Tonix Pharmaceuticals has announced a licensing deal with Katana Pharmaceuticals for its intranasal potentiated oxytocin to expand its use into metabolic disorders, in particular insulin resistance, diabetes, and obesity. The licensing deal is an addition to the company’s original purchase of oxytocin-potentiated therapy from Trigemina in June 2020, with preclinical data demonstrating the efficacy of the intranasal oxytocin product TNX-1900 in disorders of the central nervous system, with migraine chosen as the lead indication by Tonix

Und da ist der Dollar bei China Pharma

Bin gerade auch bei Celsion eingestiegen.

Moma, Atossa eingestiegen bei Direct offering 0,69. läuft gut. Schorsch hat noch Celsion gepostet, da bin ich heute rein.

Arbutus Biopharmaceutical ABUS 85m Aktien  $336m MC $102m Cash $4m burn/Monat  15% Short interest Catalysts  Additional data from AB-729 90 mg single-dose in HBV DNA positive subjects 1H Additional data from AB-729 60 mg multi-dose (4 wk / 8 wk dosing intervals) 1H / 1H Initial data from AB-729 90 mg multi-dose (8 wk / 12 wk dosing intervals) 1H / 2H Initial data from AB-729 90 mg multi-dose (8 wk dosing interval) in HBV DNA positive subjects 1H Initiate a Phase 2a combination clinical trial to evaluate AB-729 in combination with Assembly Biosciences’ lead core/capsid inhibitor candidate vebicorvir (VBR) and an NrtI 1H Initiate two Phase 2a combination clinical trials in HBV subjects; both including AB-729, with one or more approved or investigational agents 2H Initiate a Phase 1a/1b clinical trial of AB-836, our next-generation oral capsid inhibitor 1H https://investor.arbutusbio.com/static-files/7b3fdc3d-779b-4a30-9fb7-6a4be25d03d7 Arbutus hält 16% der Genevant-Anteile. Genevant hat ihre Technologie an Gritstone und Providence lizenziert um Impfstoffe gegen Covid zu entwickeln. Research Efforts to Combat COVID-19 and Future Coronavirus Outbreaks Based on its extensive antiviral drug discovery experience, Arbutus has established an internal research program to identify new small molecule antiviral medicines to treat COVID-19 and future coronavirus outbreaks. This effort, led by Dr. Michael Sofia, Arbutus’ Chief Scientific Officer, is focused on the discovery and development of new molecular entities that address specific viral targets including the nsp12 viral polymerase and the nsp5 viral protease. These targets are essential viral proteins which Arbutus has experience in targeting. Arbutus has also joined forces with the COVID R&D consortium to further support and expedite efforts to address the COVID-19 pandemic.